NCT00276575View on ClinicalTrials.gov

Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

October 31, 2012

Study Completion Date

September 30, 2014

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL

bevacizumab

DRUG

erlotinib hydrochloride

DRUG

everolimus

Trial Locations (1)

27710

Duke Comprehensive Cancer Center, Durham

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Herbert Hurwitz, MD

OTHER

NCT00276575 - Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter